STOCK TITAN

Immunic (IMUX) director Elena Ridloff receives 50,740 stock options at $14.54

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IMMUNIC, INC. director Elena Ridloff received a grant of 50,740 stock options on 2026-08-06. The options have an exercise price of $14.54 per share, are exercisable for 50,740 shares of common stock, vest in monthly installments over three years from the grant date, and expire on 2036-08-06. Following this grant, Ridloff holds 50,740 options directly.

Positive

  • None.

Negative

  • None.
Insider Ridloff Elena
Role Director
Type Security Shares Price Value
Grant/Award Stock Option F1 50,740 $0.00 $0.00
Holdings After Transaction: Stock Option — 50,740 shares (Direct)
Footnotes (1)
  1. F1. The options vest in monthly increments over a period of three years from the grant date.
Options granted 50,740 options Stock option grant to director on 2026-08-06
Exercise price $14.54 per share Conversion or exercise price of granted stock options
Underlying shares 50,740 shares Common stock underlying the stock option award
Expiration date 2036-08-06 Expiration of the granted stock options
Options held after transaction 50,740 options Total derivative holdings following the award
Stock Option financial
"security_title: Stock Option"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion or exercise price of 14.5400 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration date of 2036-08-06 for the options"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying security title is Common Stock with 50,740 shares"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did IMMUNIC, INC. (IMUX) report for Elena Ridloff?

IMMUNIC, INC. reported that director Elena Ridloff received a grant of 50,740 stock options on 2026-08-06. The options relate to the company’s common stock and were reported as a derivative acquisition.

What is the exercise price of the new IMMUNIC (IMUX) stock options granted to Elena Ridloff?

The stock options granted to Elena Ridloff have an exercise price of $14.54 per share. Each option is exercisable into one share of IMMUNIC common stock at this price after vesting.

How many IMMUNIC (IMUX) shares are underlying Elena Ridloff’s new option grant?

Elena Ridloff’s new option grant covers 50,740 underlying shares of IMMUNIC common stock. Each option corresponds to one underlying share, subject to vesting and future exercise.

What is the vesting schedule for Elena Ridloff’s IMMUNIC (IMUX) stock options?

The options granted to Elena Ridloff vest in monthly increments over three years from the 2026-08-06 grant date. This creates gradual vesting rather than a single cliff-vesting event.

When do Elena Ridloff’s IMMUNIC (IMUX) stock options expire?

Elena Ridloff’s stock options are scheduled to expire on 2036-08-06. Any unexercised options after this expiration date will no longer be exercisable for IMMUNIC common stock.

What are Elena Ridloff’s IMMUNIC (IMUX) option holdings after this Form 4 transaction?

After this grant, Elena Ridloff holds 50,740 stock options directly. This figure reflects her total reported derivative holdings following the 2026-08-06 award.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ridloff Elena

(Last)(First)(Middle)
1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$14.5408/06/2026A50,740 (1)08/06/2036Common Stock50,740$0.0050,740D
Explanation of Responses:
1. The options vest in monthly increments over a period of three years from the grant date.
/s/ Elena Ridloff08/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)